Spots Global Cancer Trial Database for pacritinib
Every month we try and update this database with for pacritinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | NCT03165734 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Physician's Cho... | 18 Years - | CTI BioPharma | |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | NCT02055781 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Best Available ... | 18 Years - | CTI BioPharma | |
| Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | NCT06218628 | Primary Myelofi... Post-polycythem... Post-essential ... Chronic Myelomo... Polycythemia Ve... Essential Throm... | Talazoparib pacritinib | 18 Years - | Fox Chase Cancer Center | |
| Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms | NCT06303193 | Myelodysplastic... | pacritinib | 12 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | NCT04404361 | COVID19 COVID-19 COVID | Pacritinib Placebo | 18 Years - | CTI BioPharma | |
| Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms | NCT04858256 | T-Cell Neoplasm Lymphoprolifera... | Pacritinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | NCT03601819 | Lymphoma, T-Cel... Lymphoma, T-Cel... Chronic Lymphoc... Lymphoprolifera... Waldenstrom Mac... Lymphoplasmacyt... Mantle Cell Lym... | Pacritinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) | NCT02410551 | Myeloproliferat... | Pacritinib Busulfan Questionnaires Phone Calls Allogeneic Stem... Fludarabine | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations | NCT02323607 | Recurrent Adult... Secondary Acute... Therapy-Related... Untreated Adult... | Pacritinib Cytarabine Daunorubicin Hy... Decitabine Laboratory Biom... Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | NCT04404361 | COVID19 COVID-19 COVID | Pacritinib Placebo | 18 Years - | CTI BioPharma | |
| Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib | NCT04884191 | Primary Myelofi... Post-Polycythem... Post- Essential... | Pacritinib | 18 Years - | CTI BioPharma | |
| Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) | NCT02469415 | Leukemia | Pacritinib 5-azacitidine Decitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) | NCT03645824 | Myelofibrosis | Pacritinib | 18 Years - 70 Years | Stichting Hemato-Oncologie voor Volwassenen Nederland | |
| A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR) | NCT04520269 | Breast Cancer | Pacritinib | 21 Years - 99 Years | National University Hospital, Singapore | |
| Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer | NCT02277093 | Colorectal Canc... | Pacritinib | 18 Years - | Washington University School of Medicine | |
| Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | NCT02564536 | Chronic Myelomo... Juvenile Myelom... Atypical Chroni... Myeloproliferat... Myelodysplastic... Myelofibrosis | Pacritinib Decitabine | 18 Years - | Washington University School of Medicine | |
| Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) | NCT03645824 | Myelofibrosis | Pacritinib | 18 Years - 70 Years | Stichting Hemato-Oncologie voor Volwassenen Nederland | |
| A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis | NCT02584777 | Primary Myelofi... | Pacritinib | 18 Years - | Takeda | |
| Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) | NCT02342353 | Non-Small Cell ... Nonsmall Cell L... Carcinoma, Non-... | Pacritinib Erlotinib | 18 Years - | Washington University School of Medicine | |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | NCT02055781 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Best Available ... | 18 Years - | CTI BioPharma | |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | NCT03165734 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Physician's Cho... | 18 Years - | CTI BioPharma | |
| Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer | NCT04635059 | Prostate Cancer | Pacritinib | 18 Years - | Medical College of Wisconsin | |
| Pacritinib in CMML | NCT06159491 | Chronic Myelomo... | Pacritinib Azacitidine | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | NCT02564536 | Chronic Myelomo... Juvenile Myelom... Atypical Chroni... Myeloproliferat... Myelodysplastic... Myelofibrosis | Pacritinib Decitabine | 18 Years - | Washington University School of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
